微創腦科學(02172.HK)上半年營收增22.89%至2.06億元,海外收入首次突破千萬
格隆匯8月26日丨微創腦科學(02172.HK)公佈,截至2022年6月30日止六個月,公司收入為人民幣2.06億元,同比增長22.89%;期內虧損為人民幣9372.9萬元,去年同期盈利為人民幣4375.1萬元。
收入增長主要由於:(1)海外收入首次突破千萬人民幣,達約人民幣1180萬元,收入主要來自於美國、韓國及歐洲地區;(2)近年獲批的創新產品包括NUMEN®可解脱栓塞彈簧圈、Bridge®椎動脈藥物洗脱支架與U-track®顱內支撐導管快速放量;及(3)市場領先產品(包括Tubridge®血流導向密網支架與Asahi®系列神經血管導絲)臨牀使用量持續增長。
報吿期內,集團有4款產品獲得國家藥監局批准,包括Diveer®顱內球囊擴張導管、NUMENSilk®三維電解脱彈簧圈、Neurohawk®顱內取栓支架及X-track®顱內遠端導管,商業化產品完整涵蓋出血性腦卒中、腦動脈粥樣硬化狹窄及急性缺血性腦卒中三大腦血管疾病領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.